en.wikipedia.org/wiki/Abdullahi_v._Pfizer,_Inc.

The Kano trovafloxacin trial litigation arose out of a clinical trial conducted by the .... ever been treated with Trovan, and then only after all other antibiotics failed.

harvardlawreview.org/2010/01/second-circuit-looks-beyond-complaint-to-find-state-action-requirement-satisfied-ae-abdullahi-v-pfizer-inc-562-f-3d-163-2d-cir-2009

2 days ago ... Second Circuit Looks Beyond Complaint To Find State Action Requirement Satisfied.

caselaw.findlaw.com/us-2nd-circuit/1442878.html

Richard Altschuler (Ali Ahmad, Cheverly, MD, on the brief), Altschuler & Altschuler, West Haven, CT, for Plaintiffs-Appellants Ajudu Ismaila Adamu, et al. Steven ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3244202

1980, 1992; Kouvaraki et al. ... Sunitinib (sunitinib malate; SU11248; SUTENT; Pfizer Inc, New York, NY) is .... The objective response rate was 9.3% in the sunitinib group versus 0% in ..... N Engl J Med 364: 514–523 [PMC free article] [ PubMed]; Yao K.A., Talamonti M.S., Nemcek A., Angelos P., Chrisman H., Skarda J., et al.

www.ebmedicine.net/topics.php?paction=showTopic&topic_id=594&ad=digest

Jan 2, 2019 ... Brown DJ, Brugger H, Boyd J, et al. Accidental ... Zafren K, Giesbrecht GG, Danzl DF, et al. Wilderness ... Skarda D, Barnhart D, Scaife E, et al.

www.journalofdairyscience.org/article/S0022-0302(94)77168-X/pdf

3Present address Pfizer Inc, Hoge Wei IO. B-1930 ... tribove (500 mg/2 wk) was given for 252 d, commencing 60 d postpartum. Al-. Page 2. 2250. WHITE ET AL.

www.mnhs.org/library/findaids/00047.xml

H.1.3B 107 September 1982, 82-1383: Debra Wyatt, et al. v. ... JCP 84-001: In re: Complaint of A. H. Robins, Inc.; JCP 84-002: In re: Complaint of E. Clairborne Robins, Jr., et al. .... Stuart Kenton Skarda. ...... Pfizer, Inc. 94-1017: United States v.

www.gastrojournal.org/article/S0016-5085(10)00006-5/pdf

See related articles, Langille M et al, on page. 322, and ... Asacol (Procter & Gamble Pharmaceuticals, Inc, Mason, ... In 2006 D'Haens et al16 reported the use of an oral ...... dosing versus conventional dosing mesalamine for maintenance of .... Sineneng (Dayton, OH), Shayne Skarda (Longview, TX), Duane Smoot.

www.jto.org/article/S1556-0864(15)33319-0/fulltext

Small-cell lung cancer (SCLC) constitutes 10-15% of all newly diagnosed lung cancers. ..... 0139 phase III study of concurrent chemotherapy and radiotherapy ( CT/RT) vs. ..... Sculier Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet, .... in NSCLC from Pfizer; All other authors have declared no conflicts of interest.